EZH2 and cancer: Consequently, pharmacological inhibition of EZH2 may represent a potential novel therapeutic approach for a subgroup of CLL patients, an enticing idea that is readily achievable, since EZH2 pharmacological inhibitors are currently in clinical trials for other types of cancer, including B cell malignancies.